Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer

Biochemical and Biophysical Research Communications

Volumn 344, Issue 2, 2006, Pages 667-674

  Leoutsakou, Theoni ^a   Talieri, Maroulio ^b   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Ovarian cancer; Prognosis; SCAFs; Splicing factors; SR proteins; SR A1; SRA1

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GREECE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646111197     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.184     Document Type: Article

References (54)

1. Caceres J.F., and Krainer A.R. Mammalian pre-mRNA splicing factors. In: Krainer A.R. (Ed). Eukaryotic mRNA Processing (1997), Oxford University Press, New York 174-212
2. Hertel K.J., and Graveley B.R. RS domains contact the pre-mRNA throughout spliceosome assembly. Trends Biochem. Sci. 30 (2005) 115-118
3. Shen H., Kan J.L., and Green M.R. Arginine-serine-rich domains bound at splicing enhancers contact the branchpoint to promote prespliceosome assembly. Mol. Cell. 13 (2004) 367-376
4. Jamison S.F., Pasman Z., Wang J., Will C., Luhrmann R., Manley J.L., and Garcia-Blanco M.A. U1 snRNP-ASF/SF2 interaction and 5′ splice site recognition: characterization of required elements. Nucleic Acids Res. 23 (1995) 3260-3267
5. Graveley B.R. Sorting out the complexity of SR protein functions. RNA 6 (2000) 1197-1211
6. Caceres J.F., Misteli T., Screaton G.R., Spector D.L., and Krainer A.R. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J. Cell Biol. 138 (1997) 225-238
7. Caceres J.F., Screaton G.R., and Krainer A.R. A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev. 12 (1998) 55-66
8. Huang Y., Yario T.A., and Steitz J.A. A molecular link between SR protein dephosphorylation and mRNA export. Proc. Natl. Acad. Sci. USA 101 (2004) 9666-9670
9. Tacke R., Chen Y., and Manley J.L. Sequence-specific RNA binding by an SR protein requires RS domain phosphorylation: creation of an SRp40-specific splicing enhancer. Proc. Natl. Acad. Sci. USA 94 (1997) 1148-1153
10. Pilch B., Allemand E., Facompre M., Bailly C., Riou J.F., Soret J., and Tazi J. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res. 61 (2001) 6876-6884
11. Smith C.W., and Valcarcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem. Sci. 25 (2000) 381-388
12. Rooke N., Markovtsov V., Cagavi E., and Black D.L. Roles for SR proteins and hnRNP A1 in the regulation of c-src exon N1. Mol. Cell. Biol. 23 (2003) 1874-1884
13. Graveley B.R., Hertel K.J., and Maniatis T. A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers. EMBO J. 17 (1998) 6747-6756
14. Theissen H., Etzerodt M., Reuter R., Schneider C., Lottspeich F., Argos P., Luhrmann R., and Philipson L. Cloning of the human cDNA for the U1 RNA-associated 70K protein. EMBO J. 5 (1986) 3209-3217
15. Blencowe B.J., Issner R., Nickerson J.A., and Sharp P.A. A coactivator of pre-mRNA splicing. Genes Dev. 12 (1998) 996-1009
16. Zhang W.J., and Wu J.Y. Sip1, a novel RS domain-containing protein essential for pre-mRNA splicing. Mol. Cell. Biol. 18 (1998) 676-684
17. Lee M.S., Henry M., and Silver P.A. A protein that shuttles between the nucleus and the cytoplasm is an important mediator of RNA export. Genes Dev. 10 (1996) 1233-1246
18. Yuryev A., Patturajan M., Litingtung Y., Joshi R.V., Gentile C., Gebara M., and Corden J.L. The C-terminal domain of the largest subunit of RNA polymerase II interacts with a novel set of serine/arginine-rich proteins. Proc. Natl. Acad. Sci. USA 93 (1996) 6975-6980
19. Bentley D.L. Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors. Curr. Opin. Cell Biol. 17 (2005) 251-256
20. Reed R. Coupling transcription, splicing and mRNA export. Curr. Opin. Cell Biol. 15 (2003) 326-331
21. Wetterberg I., Zhao J., Masich S., Wieslander L., and Skoglund U. In situ transcription and splicing in the Balbiani ring 3 gene. EMBO J. 20 (2001) 2564-2574
22. Robert F., Blanchette M., Maes O., Chabot B., and Coulombe B. A human RNA polymerase II-containing complex associated with factors necessary for spliceosome assembly. J. Biol. Chem. 277 (2002) 9302-9306
23. Misteli T., and Spector D.L. RNA polymerase II targets pre-mRNA splicing factors to transcription sites in vivo. Mol. Cell. 3 (1999) 697-705
24. Kim E., Du L., Bregman D.B., and Warren S.L. Splicing factors associate with hyperphosphorylated RNA polymerase II in the absence of pre-mRNA. J. Cell. Biol. 136 (1997) 19-28
25. Rosonina E., and Blencowe B.J. Analysis of the requirement for RNA polymerase II CTD heptapeptide repeats in pre-mRNA splicing and 3′-end cleavage. RNA 10 (2004) 581-589
26. Hirose Y., Tacke R., and Manley J.L. Phosphorylated RNA polymerase II stimulates pre-mRNA splicing. Genes Dev. 13 (1999) 1234-1239
27. Goldstrohm A.C., Greenleaf A.L., and Garcia-Blanco M.A. Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing. Gene 277 (2001) 31-47
28. Greenleaf A.L. Positive patches and negative noodles: linking RNA processing to transcription?. Trends Biochem. Sci. 18 (1993) 117-119
29. Scorilas A., Kyriakopoulou L., Katsaros D., and Diamandis E.P. Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer. Br. J. Cancer 85 (2001) 190-198
30. Katsarou M.E., Papakyriakou A., Katsaros N., and Scorilas A. Expression of the C-terminal domain of novel human SR-A1 protein: interaction with the CTD domain of RNA polymerase II. Biochem. Biophys. Res. Commun. 334 (2005) 61-68
31. Mathioudaki K., Leotsakou T., Papadokostopoulou A., Paraskevas E., Ardavanis A., Talieri M., and Scorilas A. SR-A1, a member of the human pre-mRNA splicing factor family, and its expression in col on cancer progression. Biol. Chem. 385 (2004) 785-790
32. Day Jr. T.G., Gallager H.S., and Rutledge F.N. Epithelial carcinoma of the ovary: prognostic importance of histologic grade. Natl. Cancer Inst. Monogr. 42 (1975) 15-21
33. Herbst A.L. The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am. J. Obstet. Gynecol. 170 (1994) 1099-1105 discussion 1105-1097
34. Scorilas A., Borgono C.A., Harbeck N., Dorn J., Schmalfeldt B., Schmitt M., and Diamandis E.P. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol. 22 (2004) 678-685
35. Yousef G.M., Kyriakopoulou L.G., Scorilas A., Fracchioli S., Ghiringhello B., Zarghooni M., Chang A., Diamandis M., Giardina G., Hartwick W.J., Richiardi G., Massobrio M., Diamandis E.P., and Katsaros D. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 61 (2001) 7811-7818
36. Yousef G.M., Scorilas A., Katsaros D., Fracchioli S., Iskander L., Borgono C., Rigault de la Longrais I.A., Puopolo M., Massobrio M., and Diamandis E.P. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J. Clin. Oncol. 21 (2003) 3119-3126
37. Yousef G.M., Polymeris M.E., Grass L., Soosaipillai A., Chan P.C., Scorilas A., Borgono C., Harbeck N., Schmalfeldt B., Dorn J., Schmitt M., and Diamandis E.P. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 63 (2003) 3958-3965
38. Yousef G.M., Polymeris M.E., Yacoub G.M., Scorilas A., Soosaipillai A., Popalis C., Fracchioli S., Katsaros D., and Diamandis E.P. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 63 (2003) 2223-2227
39. Borgono C.A., Fracchioli S., Yousef G.M., Rigault de la Longrais I.A., Luo L.Y., Soosaipillai A., Puopolo M., Grass L., Scorilas A., Diamandis E.P., and Katsaros D. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int. J. Cancer 106 (2003) 605-610
40. Hoffman B.R., Katsaros D., Scorilas A., Diamandis P., Fracchioli S., Rigault de la Longrais I.A., Colgan T., Puopolo M., Giardina G., Massobrio M., and Diamandis E.P. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br. J. Cancer 87 (2002) 763-771
41. Okumura M., Kondo S., Ogata M., Kanemoto S., Murakami T., Yanagida K., Saito A., and Imaizumi K. Candidates for tumor-specific alternative splicing. Biochem. Biophys. Res. Commun. 334 (2005) 23-29
42. Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B., Cho K.R., Riggins G.J., and Morin P.J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60 (2000) 6281-6287
43. Zwahlen D., Tschan M.P., Grob T.J., Peters U.R., Fink D., Haenggi W., Altermatt H.J., Cajot J.F., Tobler A., Fey M.F., and Aebi S. Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. Int. J. Cancer 88 (2000) 66-70
44. Stickeler E., Mobus V.J., Kieback D.G., Kohlberger P., Runnebaum I.B., and Kreienberg R. Intron 9 retention in gene transcripts suggests involvement of CD44 in the tumorigenesis of ovarian cancer. Anticancer Res. 17 (1997) 4395-4398
45. Galiana-Arnoux D., Lejeune F., Gesnel M.C., Stevenin J., Breathnach R., and Del Gatto-Konczak F. The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20. J. Biol. Chem. 278 (2003) 32943-32953
46. Fischer D.C., Noack K., Runnebaum I.B., Watermann D.O., Kieback D.G., Stamm S., and Stickeler E. Expression of splicing factors in human ovarian cancer. Oncol. Rep. 11 (2004) 1085-1090
47. Vikhanskaya F., and Broggini M. Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients. Int. Rev. Cytol. 219 (2002) 157-198
48. He X., Ee P.L., Coon J.S., and Beck W.T. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin. Cancer Res. 10 (2004) 4652-4660
49. Provencher D.M., Lounis H., Champoux L., Tetrault M., Manderson E.N., Wang J.C., Eydoux P., Savoie R., Tonin P.N., and Mes-Masson A.M. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell. Dev. Biol. Anim. 36 (2000) 357-361
50. Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., Whang-Peng J., Rogan A.M., Green W.R., and Ozols R.F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43 (1983) 5379-5389
51. Lau D.H., Lewis A.D., Ehsan M.N., and Sikic B.I. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res. 51 (1991) 5181-5187
52. Longman D., McGarvey T., McCracken S., Johnstone I.L., Blencowe B.J., and Caceres J.F. Multiple interactions between SRm160 and SR family proteins in enhancer-dependent splicing and development of C. elegans. Curr. Biol. 11 (2001) 1923-1933
53. Cazalla D., Newton K., and Caceres J.F. A novel SR-related protein is required for the second step of Pre-mRNA splicing. Mol. Cell. Biol. 25 (2005) 2969-2980
54. Barnard D.C., Li J., Peng R., and Patton J.G. Regulation of alternative splicing by SRrp86 through coactivation and repression of specific SR proteins. RNA 8 (2002) 526-533